The breast lesion localization market is expected to strengthen its hold on the global market at an average CAGR of 4.1% between 2022 and 2032. The market is valued at USD 256 Million in 2022 and is likely to reach USD 382 Million by 2032. Previously, the market was thriving at a slightly higher CAGR of 4.9% (2015 to 2021), ensuring a market size of USD 244 Million in 2021.
Rising cases of breast cancer led by increased government spending on the research and development of drugs and services to counter the disease are flourishing the breast lesbian localization market, enhancing the healthcare structure while spreading awareness about the early diagnosis.
Monitoring and diagnosis of cancer gain a lot of market traction for the breast lesion localization market. The increased use of advanced healthcare tools and services is leading breast cancer detection easy and confined. With the help of breast lesion localization services, the processes of imaging, screening, and scanning become smooth and easy.
As the market grows in the regions where breast cancer is the most common cancer among a lot of regions, it is attributed to the growth of the breast lesion localization market.
| Attributes | Details |
|---|---|
| Breast Lesion Localization Market CAGR (2022 to 2032) | 4.1% |
| Breast Lesion Localization Market Value (2022) | USD 256 Million |
| Breast Lesion localization Market Value (2032) | USD 382 Million |
A global study on the Breast lesion localization market shows that the rising breast cancer cases in the region are the driving factor for the market, coupled with the growing awareness around the new technologies coming into the diagnostics and healthcare sector is increasing the sales of breast lesion localization services.
Breast cancer’s early detection and screening, and treatment, according to that diagnosis, have gained a good amount of traction in the breast lesion localization market. Breast cancer is the second leading cancer-related death in women worldwide. Integration of the latest diagnosis practices with cutting-edge healthcare also makes the screening process easy.
The chances of getting breast cancer increase with the growing age as a type of adult stem cell at the root cause of breast cancer. This directly affects the myoepithelial cells, which eventually line the breast’s milk-producing liminal cells and works as tumor suppressors.
American cancer society explains that one out of eight women gets breast cancer under 45 of age. Though the number differs for women who are older than 45 years of age, approximately 2 out of 3 women develop invasive breast cancer.
Exclusive Offer: 30% Off on Regional Reports
Get a free sample report and customize your regions for a 30% discount on your regional report!
Rising chronic diseases like breast cancer and multiple diagnosis methods including early detection and screening coupled with it being the most prevalent cancer are helping the breast lesion localization market gain traction
The government initiatives are working in order to spread awareness around breast cancer, diagnosis, symptoms, surgeries, and stages that help people in fighting against breast cancer.
Government programs also promote multiple kinds of diagnosis, treatment, and screening processes that help doctors and patients understand the real-time situation, pushing the demand for breast lesion localization. Another factor that creates multiple opportunities for the market is the high capital investments of emerging economies like India and China in their healthcare sector.
These countries are currently upgrading or building their healthcare structure, spending huge amounts on the development of the infrastructure. Countries also run programs to welcome the companies that provide a direct supply chain to healthcare and diagnostics services.
The shortage of oncologists is limiting the sales of breast lesion localization systems that perform by skilled professionals. The localization of tumors, lymphedema, seroma and risk of healthy tissue excision are some of the processes that breast lesion localization has.
Other reasons that restrict the market’s growth are the FDA approvals and the uncertainty attached to it. Players that operate the breast lesion localization need to obtain nuclear regulatory clearance to get listed among the registered operators.
The breast lesion localization market is categorized by type and usage. These categories are further divided into small segments that expand their channels in multiple market spaces. These segments perform differently in multiple markets as they have a stronghold in multiple regions.
The type category is segmented into wire localization, radioisotope localization, magnetic localization, and electromagnetic localization, while the usage category is divided into breast biopsy and breast conservation (Lumpectomy).
By usage, the breast biopsy segment is the largest segment and will hold the biggest portion of the market in the forecast period. The analysis shows that the breast biopsy segment is set to thrive at a CAGR of 3.5% in the forecast period, while previously, the segment was thriving at a slightly higher CAGR of 4.0%.
Breast lesion localization market analysis explains that the factors behind the growth of this segment are its easy removal and short time span, and lower post-surgery impacts than the lumpectomy. Also, the breast biopsy can be used to remove an abnormality within the breast, while lumpectomy (Partial mastectomy) can only be used to remove breast cancer. These factors flourish the demand for breast lesion localization market.
The breast lesion localization market is divided into regions; North America, Latin America, Asia Pacific, Middle East and Africa (MEA), and Europe. The biggest market is the United States, which is flourishing at a CAGR of 3.9% between 2022 to 2032.
The region is likely to hold a market revenue of USD 136.3 Million by the end of 2032. Increasing breast cancer cases coupled with advanced diagnosis options while upgrading the healthcare system and their integration with the latest technology like AI and IOT are fueling the growth in this region.
The UK is the highest growing market globally and will hold USD 18.2 Million by the end of 2032 as it thrives on a promising CAGR of 4.4% between 2022 to 2032. Other regions like Asia pacific also flourished, with developing countries like China booming at a CAGR of 3.6% and Japan growing at a CAGR of 3.8%, while their projected values are USD 28 Million and USD 25.2 Million, respectively.
| Regions | CAGR (2022 to 2032) |
|---|---|
| United States | 3.9% |
| United Kingdom | 4,4% |
| China | 3.6% |
| Japan | 3.8% |
| South Korea | 3.0% |
Check Free Sample Report & Save 40%!
Select your niche segments and personalize your insights for smart savings. Cut costs now!
The competitive landscape of breast lesion localization is dynamic in nature and allows new competitors to thrive in the market and increase competitiveness. The companies in the market are a part of mergers and collaborations that result in increased distribution channels and market spaces. These companies focus on updating the price ranges, while making the platforms more patient friendly.
Recent Developments in the Breast Lesion Localization Market:
The breast lesion localization market is set to grow at a CAGR of 4.1% through 2032.
North America is the biggest region in breast lesion localization market that is flourishing at at a CAGR of 3.5 by 2032.
Breast Biopsy is the leading segment in the breast lesion localization market by usage, thriving at a CAGR of 3.5% through 2032.
United Kingdom has the highest growth potential in the breast lesion localization market, thriving at CAGRs of 3.5% through 2032.
| Market Value for 2023 | USD 2,594.4 million |
|---|---|
| Market Value for 2033 | USD 9,495.1 million |
| Market CAGR from 2023 to 2033 | 13.9% |
| Market Size, 2023 | USD 883.4 Million |
|---|---|
| Market Size, 2033 | USD 1.4 Billion |
| Value CAGR (2023 to 2033) | 4.8% |
| Market Valuation (2023) | USD 1.95 billion |
|---|---|
| Market Valuation (2033) | USD 7.23 billion |
| Market CAGR (2023 to 2033) | 14% |
| Market Value (2022) | USD 256 Million |
|---|---|
| Market Value (2032) | USD 382 Million |
| Market CAGR (2022 to 2032) | 4.1% |
Explore Diagnostic Devices Insights
View Reports
Breast Lesion Localization Market
Thank you!
You will receive an email from our Business Development Manager. Please be sure to check your SPAM/JUNK folder too.
